Heat shock protein amplification improves cerebellar myelination in the Npc1nih mouse model

Frances M. Platt University of Oxford

James Gray University of Oxford

María E. Fernández-Suárez University of Oxford

Maysa Falah Peninsula Medical School

D Smith

et al. See next page for additional authors

Let us know how access to this document benefits you

Recommended Citation
Platt, F., Gray, J., Fernández-Suárez, M., Falah, M., Smith, D., Smith, C., Kaya, E., Palmer, A., Fog, C., & Kirkegaard, T. (2022) 'Heat shock protein amplification improves cerebellar myelination in the Npc1nih mouse model', eBioMedicine, 86. Available at: 10.1016/j.ebiom.2022.104374
This Article is brought to you for free and open access by the Faculty of Health at PEARL. It has been accepted for inclusion in Peninsula Medical School by an authorized administrator of PEARL. For more information, please contact openresearch@plymouth.ac.uk.
Authors
Frances M. Platt, James Gray, María E. Fernández-Suárez, Maysa Falah, D Smith, C Smith, Ecem Kaya, Ashley M. Palmer, Cathrine K. Fog, and Thomas Kirkegaard

This article is available at PEARL: https://pearl.plymouth.ac.uk/pms-research/795
Heat shock protein amplification improves cerebellar myelination in the Npc1nih mouse model

James Gray,a María E. Fernández-Suárez,a Maysa Falah,a David Smith,a Claire Smith,a Ecem Kaya,a Ashley M. Palmer,b Cathrine K. Fog,b Thomas Kirkegaard,b and Frances M. Platt,*

aDepartment of Pharmacology, University of Oxford, Oxford OX1 3QT, UK
bOrphazyme A/S, Ole Maaloes Vej 3, Copenhagen DK-2200, Denmark

Summary

Background Niemann-Pick disease type C (NPC) is a rare prematurely fatal lysosomal lipid storage disease with limited therapeutic options. The prominent neuropathological hallmarks include hypomyelination and cerebellar atrophy. We previously demonstrated the efficacy of recombinant human heat shock protein 70 (rhHSP70) in preclinical models of the disease. It reduced glycosphingolipid levels in the central nervous system (CNS), improving cerebellar myelination and improved behavioural phenotypes in Npc1nih (Npc1−/−) mice. Furthermore, treatment with arimoclomol, a well-characterised HSP amplifier, attenuated lysosomal storage in NPC patient fibroblasts and improved neurological symptoms in Npc1−/− mice. Taken together, these findings prompted the investigation of the effects of HSP amplification on CNS myelination.

Methods We administered bimoclomol daily or rhHSP70 6 times per week to Npc1−/− (BALB/cNctr-Npc1mutN/J, also named Npc1nih) mice by intraperitoneal injection from P7 through P34 to investigate the impact on CNS myelination. The Src-kinase inhibitor saracatinib was administered with/without bimoclomol twice daily to explore the contribution of Fyn kinase to bimoclomol’s effects.

Findings Treatment with either bimoclomol or rhHSP70 improved myelination and increased the numbers of mature oligodendrocytes (OLs) as well as the ratio of active-to-inactive forms of phosphorylated Fyn kinase in the cerebellum of Npc1−/− mice. Additionally, treatment with bimoclomol preserved cerebellar weight, an effect that was abrogated when co-administered with saracatinib, an inhibitor of Fyn kinase. Bimoclomol-treated mice also exhibited increased numbers of immature OLs within the cortex.

Interpretation These data increase our understanding of the mechanisms by which HSP70 regulates myelination and provide further support for the clinical development of HSP-amplifying therapies in the treatment of NPC.

Funding Funding for this study was provided by Orphazyme A/S (Copenhagen, Denmark) and a Pathfinder Award from The Wellcome Trust.

Copyright © 2022 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Keywords: lysosomal storage diseases; Niemann-Pick disease type C; NPC; neurodegeneration; myelination; heat shock proteins; HSP70; cholesterol; glycosphingolipids; Fyn kinase; arimoclomol; bimoclomol; BALB/cNctr-Npc1mutN/J; Npc1nih, mice

Introduction

Niemann-Pick disease type C (NPC) is a neurovisceral lysosomal lipid storage disease caused by autosomal recessive mutations in either the NPC1 (95% of patients) or NPC2 genes leading to deficiency of NPC1 or NPC2.1 NPC is a lipid trafficking disorder, characterised by the accumulation of unesterified cholesterol, glycosphingolipids (GSLs), sphingosine and sphingomyelin, within the late endosome/lysosome.2–4 NPC disease caused by mutations in NPC1 or NPC2 is clinically similar and patients display a broad range of symptoms with varying ages of onset and severity of disease.5 The majority (90%) of patients exhibit progressive neurodegenerative disease,1 of which the
prominent neuropathological hallmarks include myelination defects and neuronal loss. Patients display hypomyelination of white matter, as well as atrophy of the cerebellum and forebrain, which have been associated with the clinical manifestations of disease including ataxia and impairments in saccadic gain.

The Npc1inh (hereafter referred to as Npc1inh) mouse arose from a spontaneous insertional mutation resulting in undetectable levels of NPC1 protein and re-emerged from a spontaneous insertional mutation resulting in infantile onset NPC, including hypomyelination and behavioural phenotypes related to cerebellar atrophy. Treatment with arimoclomol, an HSP amplifier, additionally decreased lysosomal storage in NPC patient fibroblasts and neurological symptoms in Npc1−/− mice, thereby prompting us to further investigate the roles of HSP amplification in ameliorating the defective myelination observed within the CNS in NPC.

### Added value of the study
Bimoclomol is an analogue of the well-characterised HSP amplifier, arimoclomol, an orally available, CNS-penetrant, small molecule currently in late-stage clinical development for the treatment of NPC. A recently completed clinical phase II/III trial with arimoclomol in NPC reported positive results showing a marked reduction in disease progression and significant effect on biomarkers of target engagement, specifically HSP70. The program has subsequently received Fast Track and Breakthrough Therapy designations with the US Food and Drug Administration. The data herein suggest that treatment with HSP-amplifying compounds may be a promising therapeutic strategy for improving white matter thickness and counteracting hypomyelination, which is associated with the clinical manifestations of ataxia and impaired ocular-motor functioning in NPC, and therefore provide further mechanistic detail on the disease-modifying effects of HSP amplification by this class of compounds.

### Implications of all the available evidence
In summary, the available evidence suggests that HSP-amplifying compounds may be an effective strategy for treating the neuropathological lesions and subsequent clinical manifestations of NPC.
knockout mouse model and a dystrophic (dy) mouse model (dy/dy) in which expression of the laminin 2 subunit is severely reduced.

There is no cure for NPC and the current treatment options are extremely limited. The only approved therapy for the treatment of NPC in Europe and other countries outside the US is miglustat, a GSL biosynthesis inhibitor, which inhibits glucosylceramide synthase. In Npc1−/− mice, treatment with miglustat led to reductions in CNS GSL levels and improved Purkinje cell survival, behavioural phenotypes and lifespan. Furthermore, treatment with miglustat slowed the loss of white matter in adolescent and adult-onset NPC patients and has also been shown to stabilise disease progression and extend lifespan. The heat shock protein 70 (HSP70) is capable of correcting lysosomal progression, as measured by the primary endpoint, the 5-domain NPC Clinical Severity Scale (Clinicaltrials.gov −/−). Treatment with rhHSP70 was a clear improvement in cerebellar myelination in Niemann-Pick disease type A and B (acid sphingomyelinase deficiency) fibroblasts through an intra-lysosomal mechanism of enhancing the activity of mutated acid sphingomyelinase. We recently demonstrated that recombinant human HSP70 (rhHSP70) also affects other sphingolipid hydrolases, suggesting a broader effect on lysosomal lipid metabolism. Additionally, treatment with rhHSP70 in Npc1−/− mice reduced GSL accumulation within the CNS and improved the behavioural phenotypes associated with NPC. A prominent histopathological observation in the brains of Npc1−/− mice treated with rhHSP70 was a clear improvement in cerebellar myelination. Furthermore, the small molecule arimoclomol, an orally available, CNS-penetrant, HSP amplifier, was also able to significantly improve the neurological symptoms and extend the lifespan in Npc1−/− mice. A recently completed clinical phase II/III trial with arimoclomol for the treatment of NPC reported positive results showing a reduction in disease progression, as measured by the primary endpoint, the 5-domain NPC Clinical Severity Scale (Clinicaltrials.gov identifier: NCT02612129). In addition, the biomarker data showed a clear biological effect of arimoclomol in terms of target engagement and lipid biomarkers, as evidenced by an increase in the levels of circulating HSP70 and reductions in the levels of accumulated unesterified cholesterol in skin and blood cells in patients treated with arimoclomol.

In the current study, we investigated the impact of heat shock protein amplification on CNS myelination in the Npc1−/− mouse model by treating the mice with the arimoclomol analogue, bimoclomol. Similar to arimoclomol, bimoclomol has been shown to sustain HSF1 activation and amplify HSP70 levels. We hypothesised that treatment with bimoclomol would lead to improvements in myelin formation. To test this hypothesis, Npc1−/− mice were treated with bimoclomol or rhHSP70 from P7 to P34. Treatment with either bimoclomol or rhHSP70 improved cerebellar myelination in Npc1−/− mice. This observation was accompanied by a normalisation in the numbers of mature OLs as well as increases in the ratio of active-to-inactive forms of phosphorylated Fyn kinase in the cerebellum, both of which were reduced in vehicle-treated Npc1−/− mice. Additionally, Npc1−/− mice treated with bimoclomol exhibited improvements in cerebellar weights, but not when treatment was administered in combination with saracatinib, a Src family kinase inhibitor capable of inhibiting Fyn kinase activity. Finally, treatment with bimoclomol also increased the numbers of immature OLs within the cortex. Taken together, these findings suggest that amplification of HSPs may improve the hypomyelination observed in Npc1−/− mice by increasing the numbers of mature OLs required for myelination, potentially via increased Fyn kinase-mediated signalling to the OLs and/or an expansion of the immature OL population.

Methods

Ethics

All experiments were conducted using protocols approved by the UK Home Office Animal Scientific Procedures Act, 1986. All animal usage was in compliance with the ARRIVE guidelines.

Animal studies

BALB/cNctr-Npc1m1N/J mice (termed Npc1−/− mice, also known as Npc1inh mice; RRID: IMSR_JAX:003092) were generated by heterozygote brother/sister matings obtained from Jackson Laboratory (Charles River, UK) and genotyped as previously described. Mice were bred and housed in individually ventilated cages (IVCs; Thoren, Hazleton, PA, USA) under non-sterile conditions containing Bcell8 bedding (Anibed, France) and given ad libitum access to food (i.e., standard chow) and water. Each IVC housed a total of two litters or up to five adult mice. The animals were maintained on a 12:12 light:dark cycle. Mice were assigned to treatment based on gender and genotyping result without access to information on weight or physical appearance. Individual mice were weighed prior to administration of treatments at postnatal day 7 (P7), and those mice weighing a minimum of 3.5 g were included in the study. Baseline characteristics, including weight and sex, were generally balanced, and the numbers of mice per treatment group were based on previous studies. Npc1−/− mice were intraperitoneally (IP) injected 6 times per week in the morning (between 8:00 am and 9:00 am) from P7 to P34 with recombinant human His-tagged HSP70 at 1.5 mg/kg of body weight (Npc1−/− + rhHSP70; n = 18) or bimoclomol daily at 10 mg/kg of body weight (Npc1−/− + bimoclomol; n = 17), both from Orphazyme A/S, and dissolved in phosphate buffered saline (PBS). Bimoclomol and arimoclomol are hydroxyamine compounds that amplify heat shock proteins,
including HSP70, with the structural difference being the presence of an oxide group on arimoclomol. The dosing regimen was selected to give a stable exposure to treatment that would be expected to reflect patient dosing, and the weekly dosage was the same as previously used. The control group was comprised of Npc1+/− mice IP injected daily with PBS (Npc1+/− + PBS; n = 18). Untreated Npc1+/− littermates (n = 16) served as comparators. For the Fyn kinase inhibition experiments, saracatinib (MedChemExpress) and binoclomol were IP injected daily at 10 mg/kg of body weight either alone (n = 6) or in combination (n = 6) and dissolved in hydroxypropyl methylcellulose (0.5%, Sigma Aldrich). Controls (n = 6) were injected with vehicle alone. Each treatment group contained separate cohorts of Npc1−/− and Npc1+/− mice. Due to the high clearance and low solubility of saracatinib, the daily dosage for all treatments was split with half administered in the morning (between 8:00 am and 9:00 am) and half in the afternoon (between 4:00 pm and 5:00 pm). All IP injections were administered in a sterile hood housed in the procedure room.

Mice were killed at 35 days of age with 800 mg/kg pentobarbital IP. For biochemical analysis, mice were transcardially perfused with ice-cold PBS. The brains were removed and dissected into cerebellum, corpus callosum, or cortex, snap frozen on dry ice, and stored at −80 °C. For immunofluorescence, mice were transcardially perfused with 10 mL PBS followed by 40 mL 4% paraformaldehyde (PFA) in PBS. Brains were removed and post-fixed overnight in 4% PFA before washing three times in PBS and cryoprotecting in 30% sucrose solution. For electron microscopy, grids were post-stained with 1% uranyl acetate solution and re-embedded in resin blocks. Ultrathin sections (70 nm) were cut using an Ultracut UCT ultramicrotome (Leica Instruments) and mounted onto grids. Prior to electron microscopy, sections were post-stained with lead citrate for 3 min at room temperature before air-drying. Imaging was done using a Tecnai 12 (FEI) transmission electron microscope (TEM) microscope operated at 120 kV and equipped with a Oneview camera (Gatan).

Immunofluorescence

Brains were cut into 6 series of floating sagittal sections at 20 μm thickness using a VT1000s vibratome, (Leica Instruments) into 6 serial sections and washed three times in 0.1 M phosphate buffer. Sections were incubated with 1% osmium tetroxide for 1 h before dehydrating in a series of washes from 50% to 100% ethanol. Sections were then incubated with a 1% uranyl acetate solution for 40 min before further dehydration in a series of washes from 50% to 100% ethanol. Sections were impregnated with Durcupan resin (Sigma–Aldrich) before baking overnight at 60 °C. For each condition, the cerebellar lobule VIII was dissected from the tissue and re-embedded in resin blocks. Ultrathin sections (70 nm) were cut using an Ultracut UCT ultramicrotome (Leica Instruments) and mounted onto grids. Prior to electron microscopy, grids were post-stained with lead citrate for 3 min at room temperature before air-drying. Imaging was done using a Tecnai 12 (FEI) transmission electron microscope (TEM) microscope operated at 120 kV and equipped with a Oneview camera (Gatan).

Western blotting

For protein expression, dissected tissues were weighed prior to homogenisation in 40 volumes of RIPA buffer containing 1× Halt™ protease inhibitor cocktail (Thermo Fisher) and phosphatase inhibitor cocktail (Invitrogen). Homogenates were agitated on ice for 20 min before centrifugation at 12,000g for 10 min. The protein concentration of lysates was determined using the bicinchoninic acid (BCA) assay (Sigma–Aldrich). For Western blotting, samples each containing 15 μg protein were separated using Nu-PAGE 4–12% bis-tris gradient gels (BioRad) before transferring onto PVDF membranes (Biorad) and blocking in PBS containing 0.5% Tween-20 and 5% defatted milk powder for 1 h at room temperature. Blots were probed with primary mouse monoclonal antibodies against MBP (BioLegend Cat# 836504, RRID: AB_2616694) or myelin 2,3-cyclic nucleotide-3′-phosphodiesterase (CNPase; BioLegend Cat# 21043, RRID: AB_2535712), and rabbit IgG (Alexa Fluor 568; Thermo Fisher Scientific Cat# A-12043, RRID: AB_2535712), and rabbit IgG (Alexa Fluor 568; Thermo Fisher Scientific Cat# A-11011, RRID: AB_143157) were each applied at 1:1000 for 2 h at room temperature. Following three washes in PBS, sections were then counterstained with DAPI (300 nM in PBS, Sigma–Aldrich) for 30 min before washing three times with PBS. Sections were mounted onto Superfrost™ slides, air-dried overnight, and protected from light before addition of coverslips with ProLong® Gold mounting medium. Confocal images were acquired using a Leica-SP8 confocal microscope with an LD 20× water objective.

Electron microscopy

Coronal sections of cerebellum were cut at 70 μm thickness using a VT1000s vibratome, (Leica Instruments) into 6 serial sections and washed three times in 0.1 M phosphate buffer. Sections were incubated with 1% osmium tetroxide for 1 h before dehydrating in a series of washes from 50% to 100% ethanol. Sections were then incubated with a 1% uranyl acetate solution for 40 min before further dehydration in a series of washes from 50% to 100% ethanol. Sections were impregnated with Durcupan resin (Sigma–Aldrich) before baking overnight at 60 °C. For each condition, the cerebellar lobule VIII was dissected from the tissue and re-embedded in resin blocks. Ultrathin sections (70 nm) were cut using an Ultracut UCT ultramicrotome (Leica Instruments) and mounted onto grids. Prior to electron microscopy, grids were post-stained with lead citrate for 3 min at room temperature before air-drying. Imaging was done using a Tecnai 12 (FEI) transmission electron microscope (TEM) microscope operated at 120 kV and equipped with a Oneview camera (Gatan).
expression were quantifying the Pierce ECL western blotting substrate (Thermo Fisher) for 20 min. Blots were then rinsed with water and before transferring to 5:4:1 methanol:water:acetic acid in 1:1 methanol:water containing 0.1% Coomassie Blue. Protein loading was quantified using a mouse monoclonal anti-β actin HRP conjugated antibody at 1:25,000 (Sigma–Aldrich Cat# A3854, RRID: AB_262011). For saracatinib experiments, due to the effects of saracatinib on actin-ring formation,39 blots were normalised by Coomassie staining as previously described.15 Briefly, after processing, blots were washed three times with PBS containing 0.5% Tween-20 and incubated for 1 min in 1:1 methanol:water containing 0.1% Coomassie Blue before transferring to 5:4:1 methanol:water:acetic acid for 20 min. Blots were then rinsed with water and allowed to air-dry. Immunoreactivity was visualised using the Pierce ECL western blotting substrate (Thermo Fisher). Total protein, loading controls and protein expression were quantified using ImageLab software (version 3.0, BioRad).

**Immunoprecipitation**

Protein A Dynabeads (Invitrogen) were incubated with a rabbit polyclonal antibody against Fyn (Santa Cruz Biotechnology Cat# sc-16, RRID: AB_631528) at 1:2000 for 10 min at room temperature. Unbound antibody was washed from beads with PBS and the beads were conjugated using BS3 (Thermo Scientific) according to manufacturer’s instructions before resuspending in original bead volume in PBS containing 0.1% Tween-20. For immunoprecipitation of Fyn, cerebellar homogenates were adjusted to 1 mg/mL protein in RIPA buffer containing Halt protease and phosphatase inhibitors. Protein (200 µg) was then incubated with 40 µL of the Dynabead-antibody complex at 4 °C for 1 h. Following incubation, the unbound fraction was collected, and the beads were washed 3 times before incubating at 70 °C for 10 min in Laemmli buffer without β-mercaptoethanol. The supernatant was separated from the beads and boiled for 5 min in the presence of β-mercaptoethanol. Bound and unbound fractions were then separated by electrophoresis as described above. Blotted membranes were blocked in PBS with 0.5% Tween-20 containing 5% BSA for 1 h at room temperature. Blots were then probed with primary antibodies against phosphorylated Src (Y418) (rabbit polyclonal; Millipore Cat# 07-909, RRID: AB_568805), Fyn (phospho Y530) and Yes (phospho Y537) (rabbit monoclonal; Abcam, Cat# ab188139), and total Fyn (mouse monoclonal; Abcam Cat# ab18881, RRID: AB_2232153) at 1:1000, 1:5000, and 1:1000 overnight, respectively, before probing with secondary antibodies as described previously. Blots were developed with Pierce SuperSignal West-Femto substrate (Thermo Fisher).

**Image analysis**

All image analysis, counts, and quantifications were performed using ImageJ (Fiji) software (version 2.0.0, ImageJ). For quantification of MBP staining, the exterior of the MBP-positive white matter region was outlined, and the total area calculated as a proportion of the total lobular area (as assessed by DAPI staining). Counts of pi-GST- and O4-positive cells were performed manually and adjusted for the total area per field of view of deep cerebellar white matter, corpus callosum, or cortex as applicable. The quantification of proportions of myelinated fibres was performed from 6,800x magnified TEM images of cerebellar white matter (minimum of 500 axons/animal). Axons were identified as single membrane ensheathed structures containing multiple bands of neurofilament, either with or without myelin ensheathment. Measurements of the g-ratio were taken from randomly selected myelinated axons (minimum 50/animal) of TEM images at 12,000x magnification. Axonal and myelin diameter was estimated by dividing the total circumference by pi. The g-ratio was calculated by dividing the estimated axonal diameter by the estimated axonal diameter plus myelin diameter.

**Statistical analysis**

Data were compiled in Microsoft Excel for Mac (version 15.37, Microsoft). Statistical analyses were performed using Prism (version 7.0, GraphPad) on log-transformed values to better satisfy the model assumptions for analysis of variance (ANOVA); a full description of the methods is detailed in each of the figure legends. The comparator group was not included in the statistical analyses, except where indicated, as we have previously shown that Npc1−/− mice exhibit hypomyelination and significantly reduced levels of MBP compared with Npc1+/- mice. Therefore, we used the a priori comparisons between vehicle (PBS)-treated Npc1−/− mice and Npc1−/− mice treated with either rhHSP70 or bimoclomol to assess the effects of treatments. Multiplicity was adjusted using Dunnett’s method (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).

**Results**

**Amplification of heat shock proteins increases myelin basic protein levels in vivo**

We previously showed that treatment with rhHSP70 significantly increased MBP levels in the cerebellum of Npc1−/− mice when administered from three weeks of age.43 As myelination begins before P7 in the murine CNS and is significantly advanced by 14 days...
postnatally, we treated *Npc1*−/− mice with 1.5 mg/kg rhHSP70, six times per week, or 10 mg/kg bimoclomol, daily, from P7 until P34. This treatment window corresponds to the period of myelin formation in the human CNS, which begins shortly after birth, peaks at around one year of age, and, in some cortical regions, continues into early adulthood. The expression of myelin-specific proteins, CNPase and MBP, in the cerebellum of five-week-old mice (P35) was measured by Western blotting. Treatment with either rhHSP70 or bimoclomol significantly increased MBP expression in the cerebellum of *Npc1*−/− mice compared with vehicle (PBS)-treated controls (p < 0.0001 and p = 0.0003, respectively; nested one-way ANOVA; Fig. 1a and b) whereas CNPase expression was unchanged (Fig. 1a and b). Cerebellar sections were then stained with MBP to assess the extent of myelination. Compared with wild-type comparators, MBP-positive white matter qualitatively appeared thinner in vehicle-treated *Npc1*−/− mice, a phenotype which improved with the treatment of either rhHSP70 or bimoclomol (Fig. 1c).

To quantify the changes in MBP-positive white matter, we measured the area of MBP-positive white matter in a late degenerating cerebellar lobe (lobule VIII) as a proportion of the total lobular area. Treatment with either rhHSP70 or bimoclomol significantly increased cerebellar white matter thickness compared with vehicle-treated *Npc1*−/− mice (p < 0.0001 and p = 0.0003, respectively; nested one-way ANOVA; Fig. 1d).

**Treatment with rhHSP70 and bimoclomol improves myelination formation in *Npc1*−/− mice**

To assess whether the increases in MBP levels following treatment with rhHSP70 or bimoclomol improved the formation of functional myelin, we performed TEM on cerebellar lobule VIII sections as this is a lobe that degenerates late in the disease course, so axons are preserved longer and thus removes degeneration as a confounding factor. Wild-type mice displayed well-myelinated white matter tracts (Fig. 2a), and...
approximately 60% of the total visible axons were myelinated (Fig. 2e). In contrast, vehicle-treated Npc1−/− mice exhibited reduced numbers of myelinated axons (Fig. 2b) with only 30% of visible axons myelinated (Fig. 2e). Npc1−/− mice treated with either rhHSP70 (Fig. 2c) or bimoclomol (Fig. 2d) displayed significantly improved numbers of myelinated axons compared with vehicle-treated controls (p = 0.022 and p = 0.026, respectively; nested one-way ANOVA; Fig. 2e). Values calculated for the g-ratio, a structural and functional index of axonal myelination, showed that of the axons which were myelinated, there were no significant differences between Npc1−/− mice treated with PBS and either treatment group (Fig. 2f).

Amplification of heat shock proteins normalises the number of mature OLs in the cerebellum and increases the population of immature OLs in the cortex of Npc1−/− mice

The hypomyelination observed in Npc1−/− mice has been suggested to be due to impaired differentiation of OL lineage cells. To assess whether the treatment effects of both rhHSP70 and bimoclomol were due to changes in the number of OLs, we stained for the mature OL marker pi-GST (Fig. 3a) and immature OL marker O4 (Fig. 3b), and co-stained with MBP to delineate total white matter area in the respective CNS regions (Fig. S1a and b). Vehicle-treated Npc1−/− mice exhibited reductions in the numbers of pi-GST-positive

Fig. 2: Treatment with HSP70 and bimoclomol improves myelination formation in Npc1−/− mice. Electron micrographs of cerebellar white matter in a) untreated Npc1+/+ mice and Npc1−/− mice treated with b) PBS, c) rhHSP70, or d) bimoclomol. Scale bar represents 1 μm. e) Myelinated axons as a percentage of total axons in each field of view f) g-ratios calculated from >50 randomly selected myelinated axons. Data are shown as mean ± SD from 3 to 4 images per animal from a total of n = 2 animals per treatment group. Effects of treatments were analysed using a nested one-way ANOVA on log-transformed values and multiplicity was adjusted using Dunnett’s method (n = 2 comparisons; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).
Fig. 3: Amplification of heat shock proteins normalises the number of mature OLs in the cerebellum and increases the population of immature OLs in the forebrain of Npc1−/− mice. Representative images of OL lineage cells stained for a) pi-GST and b) O4 in the cerebellum and forebrain of Npc1+/+ mice or Npc1−/− mice treated with PBS, rhHSP70, or bimoclomol. White arrowheads indicate representative pi-GST or O4-positive cells.
OLs within the cerebellum when compared with wild-type animals (Fig. 3c). Consistent with the improvement of myelination, treatment with either rhHSP70 or bimoclomol normalised the number of pi-GST-positive OLs within the cerebellum (p = 0.0009 and p = 0.0051, respectively; nested one-way ANOVA; Fig. 3c). The development of OLs from an immature to mature phenotype has been shown to be impaired in Npc1−/− mice, resulting in an increase in the number of pre-myelinating OLs, particularly within the forebrain. We observed an increase in the number of O4-positive preoligodendrocyte cells in vehicle-treated Npc1−/− mice (Fig. 3d). Surprisingly, treatment with bimoclomol significantly increased the number of O4-positive OLs within the cortex (p = 0.0316; nested one-way ANOVA of Npc1−/− mice, suggesting an expansion of the immature OL population (Fig. 3d).

Heat shock protein amplification increases the ratio of active-to-inactive phosphorylated forms of Fyn kinase in the cerebellum of Npc1−/− mice

Fyn kinase is a critical regulator of myelination and its activity is primarily controlled through phosphorylation of two tyrosine residues, tyrosine 418 (Y418) and tyrosine 531 (Y531).24-26

To assess whether rhHSP70 and bimoclomol affected the activation of Fyn kinase, we immunoprecipitated Fyn protein in cerebellar samples from wild-type comparators or Npc1−/− mice treated with PBS (vehicle), rhHSP70, or bimoclomol and probed for the active (pY418) and inactive (pY531) forms of Fyn (Fig. 4a). Vehicle-treated Npc1−/− mice showed a reduction in the ratio of Fyn pY418:pY531 in the cerebellum (Fig. 4b). Treatment with either rhHSP70 or bimoclomol (p = 0.009 and p = 0.004, respectively; one-way ANOVA; Fig. 4b) significantly increased this ratio.

Treatment with bimoclomol improves cerebellar atrophy in Npc1−/− mice, which is blocked by the Fyn kinase inhibitor saracatinib

To determine the contribution of Fyn kinase on the improvement of the myelination defect in Npc1−/− mice, we administered the Src family kinase inhibitor saracatinib, which has a half maximal inhibitory concentration (IC50) of 10 nM for Fyn kinase49 and has shown preclinical efficacy in a mouse model of Alzheimer’s disease.55,56 Whilst treatment with saracatinib alone did not affect the expression of MBP in Npc1−/− mice, bimoclomol treatment again significantly increased the expression of MBP in Npc1−/− mice when compared to vehicle treated Npc1−/− mice (p = 0.028; two-way ANOVA; Fig. 5a). This increase was blocked by coadministration of saracatinib with bimoclomol (Fig. 5a). Interestingly, the significant increase in Fyn expression observed in Npc1−/− mice treated with bimoclomol was not affected by saracatinib co-administration (Fig. 5b).

---

O4-positively labelled OL lineage cells. Scale bars represent 30 μm. Quantification of cells positively labelled for c) pi-GST and d) O4 in the cerebellum (Cb), corpus callosum (CC) and cortex (Ctx). Data are shown as mean ± SD of the number of labelled cells per square micron. Effects of treatments were analysed by a nested one-way ANOVA on log-transformed values and multiplicity was adjusted using Dunnett’s method (n = 2 comparisons; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). Npc1+/+, n = 4; Npc1−/− + PBS, n = 6; Npc1−/− + rhHSP70, n = 6; Npc1−/− + bimoclomol, n = 5. For images stained for pi-GST, 3–7 images per animal were analysed. For images stained for O4 in treated Npc1−/− mice, 3–5 images per animal were analysed and 1–3 images per animal were analysed from Npc1+/+ mice.
Treatment with either saracatinib or bimoclomol alone or in combination did not alter the expression of MBP or Fyn in \( \text{Npc1}^{-/-} \) mice. Vehicle-treated \( \text{Npc1}^{-/-} \) mice exhibited a reduction in cerebellar weights compared with those of vehicle-treated wild-type mice (Fig. 5c). Furthermore, treatment with saracatinib resulted in a significant reduction of cerebellar weights in wild-type mice compared with those of vehicle-treated wild-type mice (\( p = 0.041 \); two-way ANOVA; Fig. 5c). Bimoclomol administered both alone and in combination with saracatinib did not have a significant effect on cerebellar weights compared to control in wild-type mice. Interestingly, in \( \text{Npc1}^{-/-} \) mice, treatment with bimoclomol prevented cerebellar atrophy and preserved cerebellar weights at wild-type weights (\( p = 0.025 \); two-way ANOVA), whereas this improvement was blocked by co-administration with saracatinib (Fig. 5c). Treatment with saracatinib alone resulted in a small, non-significant decrease in cerebellar weights.

**Discussion**

Our findings suggest that amplification of HSPs may be a promising strategy for treating hypomyelination in NPC, a progressive and prematurely fatal neurovisceral disease with limited therapeutic options. We have utilised the \( \text{Npc1}^{\text{inh}} \) mouse model to address whether direct application of rhHSP70 or drug-modulated HSP amplification with the arimoclomol-analogue bimoclomol could improve the prominent hypomyelination observed within the CNS. The current study was motivated by previous findings showing that treatment with rhHSP70 in \( \text{Npc1}^{-/-} \) mice significantly improved cerebellar white matter thickness and MBP levels as well as the behavioural phenotypes associated with NPC.

Here, we demonstrate that treatment with either rhHSP70 or bimoclomol improves cerebellar myelination in \( \text{Npc1}^{-/-} \) mice, as evidenced by increased MBP levels and myelin formation. CNPase, another component of myelin was unchanged by treatment, the reason for this is unclear. CNPase is both present in pre-myelinating OLs as well as activated microglia. Reductions observed in NPC disease therefore may not be due only to differences in OL CNPase expression but deficiencies in other cell types as well. Interestingly, CNPase deficient mouse models show no overt myelin defects. Both treatment with rhHSP70 and bimoclomol normalised the numbers of mature OLs and increased the ratio of active-to-inactive forms of phosphorylated Fyn kinase in the cerebellum. Furthermore, treatment with bimoclomol improved MBP expression, prevented cerebellar atrophy and preserved cerebellar weights at wild-type weights in a separate cohort of \( \text{Npc1}^{-/-} \) mice; these effects were blocked by co-administration with the Fyn kinase inhibitor, saracatinib. The improvements were associated with a small but significant increase in Fyn expression in \( \text{Npc1}^{-/-} \) mice treated with bimoclomol. Finally, bimoclomol-treated mice exhibited an expansion of the immature OL population in the cortex, an effect which...
seems insufficient on its own to initiate significant myelination at this stage of development. Taken together, these findings suggest that HSP amplification in Npc1−/− mice improves cerebellar myelination and rescues cerebellar atrophy by normalising the population of mature OLs required for proper myelin formation, potentially through a Fyn kinase-mediated mechanism though further work is needed to confirm that saracatinib blocked myelination through inhibition of Fyn phosphorylation.

The association between impaired OL maturation and hypomyelination in disease models of NPC has been reported by others; however, the underlying mechanisms are not fully understood. Several explanations have been posited including the downregulation of transcriptional regulators governing OL differentiation and impaired signalling pathways, including through polysialylated axonal NCAM, altered adenosine A2A receptor function and aberrant phosphorylation of Fyn kinase. In the current study, treatment with either rhHSP70 or bimoclomol improved myelination and normalised the numbers of mature OLs within the cerebellum of Npc1−/− mice, a finding that was associated with increased activation of Fyn, whose activity is mediated in part by the interaction between the α6β1-integrin complex and laminin-2 on the cell membrane of proliferating OLs. Interestingly, reduced cell surface expression of β1-integrins has been observed in NPC1 mutant fibroblasts, likely due to alterations in intracellular trafficking and subsequent recycling to the plasma membrane as a result of the low density lipoprotein-derived cholesterol sequestered within late endosomes. Given the critical role of integrins in cell migration and adhesion, it is possible that a reduction in β1-integrins on the cell surface of proliferating OLs could explain the observed impairments in OL maturation in Npc1−/− mice. The mature OLs are likely responsible for the functional improvements in cerebellar myelination; however, it is unclear whether the mature OL pool is driven by the increased number of forebrain-derived immature OLs, a population that could potentially migrate to the cerebellum during development or whether this expansion is the result of increased maturation signalling to the OLs. The reason why the large population of immature OLs in the forebrain do not translate into mature OLs is not clear. A previous study of HSP70 in Npc1−/− mice also indicated that forebrain myelin was not improved. Whether different signals for myelination exist between forebrain and cerebellum, or this is due to differences in disease progression between the two regions in NPC disease remains to be determined. A further point to note is that myelin is a lipid dense structure and the effects observed in this study may be due to alterations in lipid homeostasis, a previously observed effect of HSP70 in NPC. A limitation of this study is that we are unable to confirm the impact of hypomyelination on disease progression relative to other contributing pathologies. Further studies could be undertaken to determine the impact of myelination on disease course, and to elucidate the relative contributions of lipid metabolism, OL numbers and Fyn phosphorylation to the observed effects.

The above findings strongly suggest that amplification of HSPs may hold promise for treating the myelination impairments in NPC, a pathological process that has been associated with ataxia and saccadic gain in adult NPC patients. One question that remains to be answered is the role of demyelination in the neuropathology of NPC. Rescue of myelination clearly improves behavioural outcomes and prevents the cerebellum from atrophy, but it is not known whether the improvements in functional myelin can prevent the degeneration of cerebellar Purkinje neurons, a pathological process that has been observed in both murine and feline models of NPC. Widespread reductions in white matter tracts at the expense of localised reductions in grey matter in adult NPC patients and neuronal loss in a patient with late infantile onset NPC support the hypothesis that impairments in myelination and axonal morphology may precede the neurodegeneration in NPC.

The current therapeutic options for treating NPC are limited. Miglustat has been shown to slow the loss of white matter in adolescent and adult-onset NPC patients who received treatment for a median of 2.8 years. Here, we show that treatment with both rhHSP70 and the arimoclomol-analogue bimoclomol improves functional myelin formation in vivo. A recent clinical phase II/III trial with arimoclomol in NPC showed significant increases in the levels of HSP70, reduction of biomarkers of disease burden and clear reduction in clinical disease progression suggesting that amplification of HSPs may be a promising strategy for treating NPC.

In summary, we suggest that HSP-amplifying compounds constitute a viable first-in-class therapeutic option for NPC, a progressive disease for which there is a shortage of effective treatments.

Contributors
Study design: J.G., T.K., F.M.P. Data collection: J.G., M.E.F.-S., M.F., D.S., C.S., E.K. Data analysis: J.G., M.E.F.-S., M.F., E.K., A.M.P., C.K.F. Data interpretation: J.G., A.M.P., C.K.F., T.K., F.M.P. Data validation: J.G., M.E.F.-S., A.M.P. Figures: J.G., M.F., A.M.P., F.M.P. Writing: J.G., A.M.P., C.K.F., T.K., F.M.P. All authors read and approved the final version of the manuscript.

Data sharing statement
All data needed to understand the methodology and evaluate the conclusions in the paper are present in the paper.

Declarations of interests
A.M.P., C.K.F., and T.K. are former employees of Orphazyme A/S. T.K. holds shares in Orphazyme A/S. T.K. is a founder of Orphazyme A/S. J.G. was funded in part by Orphazyme A/S. M.F. and M.E.F.-S. were funded by Orphazyme A/S. F.M.P. is a former consultant to Orphazyme A/S. C.S., D.S. and E.K. declare no conflict of interests.
Acknowledgments
The authors would like to thank Errin Johnson from the Dunn School EM Facility at Oxford University for assistance with TEM imaging, Kristina Wagner and Professor Peter Somogyi from the Pharmacology at Oxford University for assistance with sample preparation for TEM, and Thomas Hansen (Orphazyme A/S) for helpful advice on statistical methods.

Funding for this study was provided by Orphazyme A/S, Copenhagen, Denmark and a Pathfinder Award from The Wellcome Trust (award number: 105687/Z/14/Z). FP is a Wellcome Trust Investigator in Science and a Royal Society Wolfson Merit Award holder. Orphazyme A/S was involved in the study design, data analysis, data interpretation and writing.

Appendix A. Supplementary data
Supplementary data related to this article can be found at https://doi.org/10.1016/j.ebiom.2022.104374.

References
1. Vanier MT. Niemann-Pick disease type C. Orphanet J Rare Dis. 2010;5:16.
2. Hammond N, Mukacsi AB, Sturley SL. The complexity of a complex lipid trafficking network in Niemann-Pick type C disease. Biochim Biophys Acta Mol Cell Biol Lipids. 2019;1864(8):1109–1123.
3. Vanier MT. Complex lipid trafficking in Niemann-Pick disease type C. J Inherit Metab Dis. 2015;38(1):187–199.
4. Lloyd-Evans E, Platt FM. Lipids on trial: the search for the offending metabolite in Niemann-Pick type C disease. Traffic. (Copenhagen, Denmark). 2010;11(4):419–428.
5. Pineda M, Juríčková K, Karimzadeh P, et al. Disease characteristics, prognosis and miglustat treatment effects on disease progression in patients with Niemann-Pick disease type C: an international, multicenter, retrospective chart review. Orphanet J Rare Dis. 2019;14(1):32.
6. Patterson MC, Mengel E, Vanier MT, et al. Stable or improved neurological manifestations during miglustat therapy in patients from the international disease registry for Niemann-Pick disease type C: an observational cohort study. Orphanet J Rare Dis. 2015;10(1):65.
7. Kodachi T, Matsumoto S, Mizuguchi M, et al. Severe demyelination in a patient with a late infantile form of Niemann-Pick disease type C. Neuropathology. 2017;37(5):426–430.
8. Walterfang M, Fahey M, Desmond P, et al. White and gray matter alterations in adults with Niemann-Pick disease type C: a cross-sectional study. Neurology. 2010;75(1):49–56.
9. Walterfang M, Abel LA, Desmond P, Fahey MC, Bowman EA, Velakoulis D. Cerebellar volume correlates with saccadic gain and ataxia in adult Niemann-Pick disease type C. Mol Genet Metab. 2013;108(1):85–89.
10. Gilbert EF, Callahan J, Viseskul C, Opitzy JM. Niemann-Pick disease type C. Eur J Pediatr. 1981;136:263–274.
11. Walterfang M, Fahey M, Abel L, et al. Size and shape of the corpus callosum in adult Niemann-Pick type C reflects state and trait illness variables. Am J Neuroradiol. 2011;32(7):1340–1346.
12. Huang J-Y, Peng S-F, Yang C-C, Yen K-Y, Tzen K-Y, Yen R-F. Proteomics of the corpus callosum to identify novel factors involved in hypomyelination Niemann-Pick Type C disease mice. Mol Brain. 2019;12(1):17.
13. Takikita S, Fukuda T, Mohri I, Yagi T, Suzuki K. Perturbed myelination process of premyelinating oligodendrocyte in Niemann-Pick type C mouse. J Neuroeph Exp Neurol. 2004;63(6):660–673.
14. Higashi Y, Murayama S, Pentchev PG, Suzuki K. Cerebellar degeneration in the Niemann-Pick type C mouse. Acta Neuropathol. 1993;85(2):175–184.
15. Sarna JR, Larouche M, Marzbain H, Sillitoe RV, Rancourt DE, Hawkes R. Patterned Purkinje cell degeneration in mouse models of Niemann-Pick type C disease. J Comp Neurol. 2003;456(3):279–291.
16. Baumann N, Pharm-Dinh D. Biology of oligodendrocyte and myelin in the mammalian central nervous system. Physiol Rev. 2001;81(2):871–927.
17. Salzer JL. Zalck B. Myelination. Curr Biol. 2016;26(20):R971–R975.
18. Emerly B, Agulliu D, Cahoy JD, et al. Myelin gene regulatory factor is a critical transcriptional regulator required for CNS myelination. Cell. 2009;138(1):172–185.
19. Colognato H, Galvin J, Wang Z, et al. Identification of dystroglycan as a second laminin receptor in oligodendrocytes, with a role in myelination. Development. 2007;134(9):1723–1736.
20. O’Meara PW, Michalick J-P, Kohary R. Structural signaling in oligodendrocytes and its importance in CNS myelination. J Signal Transduc. 2011;1:1–11.
21. Umemori H, Satot S, Yagi T, Aizawal S, Yamamoto T. Initial events of myelin formation involve Fyn tyrosine kinase signalling. Nature. 1994;367(6463):572–576.
22. Laursen LS, Chan CW, Ffrench-Constant C. An integrin-contactin complex regulates CNS myelination by differential Fyn phosphorylation. J Neurosci. 2009;29(29):9174–9185.
23. Goffoni S, Weijland A, Kretzschmar J, Superti-Furga G. Crosstalk between the catalytic and regulatory domains allows bidirectional regulation of Src. Nat Struct Biol. 2000;7(6):281–286.
24. Hubbard SR. Src autoinhibition: let us count the ways. Oncogene. 1991;10(4):733–743.
25. Umemori H, Satot S, Hirosawa K, et al. Src is a critical transcriptional regulator required for CNS myelination. Mol Cell Biol. 1999;19(4):1393–1397.
26. Osterhout DJ, Wolven A, Wolf RM, Shli MD, Chao MO. Morphological differentiation of oligodendrocytes requires activation of Fyn tyrosine kinase. J Cell Biol. 1999;145(6):1209–1218.
27. Yu T, Lieberman AP. Npc1 acting in neurons and glias is essential for the formation and maintenance of CNS myelin. PLoS Genet. 2011;7(9):e1002462.
28. Relacuo J, Tavetanova ID, Ao W, Lindquist S, Colognato H. Laminin alters Fyn regulatory mechanisms and promotes oligodendrocyte development. J Neurosci. 2009;29(38):11794–11806.
29. Platt FM, D’azzo A, Davidson BL, Neufeld EF, Tiffit CJ. Syntrophin. J Neurosci Res. 2004;81(4):564–568.
30. Platt FM, Neises GR, Dwek RA, Butters TD. N-butyldeoxynojirymycin is a novel inhibitor of glycolipid biosynthesis. J Biol Chem. 1994;269(11):8362–8365.
31. Lachmann RH, Te Vruchte D, Lloyd-Evans E, et al. Treatment with miglustat reverses the lipid-trafficating defect in Niemann-Pick disease type C. Neurology. 2004;63(4):654–658.
32. Bowman EA, Walterfang M, Abel L, Desmond P, Fahey M, Velakoulis D. Longitudinal changes in cerebellar and subcortical volumes in adult-onset Niemann-Pick disease type C patients treated with miglustat. J Neurosci. 2015;35(29):2106–2114.
33. Pineda M, Walterfang M, Patterson MC. Miglustat in Niemann-Pick disease type C patients: a review. Orphanet J Rare Dis. 2018;13(1):140.
34. Patterson MCC, Mengel E, Vanier MT, Monescu P, Rosenberg D, Pineda M. Treatment outcomes following continuous miglustat therapy in patients with Niemann-Pick disease type C: a final report of the NPC Registry. Orphanet J Rare Dis. 2020;15(1):104.
35. Patterson MC, Garver WS, Giugliani R, et al. Long-term survival outcomes of patients with Niemann-Pick disease type C receiving miglustat treatment: a large retrospective observational study. J Inherit Metab Dis. 2020;43(5):1060–1069. https://doi.org/10.1002/jim.21245.
52 Ammer AG, Kelley LC, Hayes KE, et al. Saracatinib impairs head and neck squamous cell carcinoma invasion by disrupting invadopodia function. J Cancer Sci Ther. 2009;1(2):52.

53 Welinder C, Ekblad L. Cooxamssie staining as leading control in western blot analysis. J Proteome Res. 2011;10(3):1416–1419.

54 Williamson JM, Lyons DA. Myelin dynamics throughout life: an ever-changing landscape? Front Cell Neurosci. 2018;12:1–8.

55 Kaufman AC, Salazar SV, Haas LT, et al. Fyn inhibition rescues established memory and synapse loss in Alzheimer mice. Ann Neurol. 2015;77(6):953–971.

56 Smith LM, Zhu R, Strittmatter SM. Disease-modifying benefit of Fyn blockade persists after washout in mouse Alzheimer’s model. Neuropharmacology. 2018;130:54–61.

57 Yang I, Kan EM, Lu J, Wu C, Ling E-A. Expression of α2,3-cylophosphodiesterase (CNPase) and its roles in activated microglia in vivo and in vitro. J Neuroinflammation. 2014;11:148.

58 Yan X, Lukas J, Witt M, et al. Decreased expression of myelin gene regulatory factor in Niemann-Pick type C 1 mouse. Metab Brain Dis. 2011;26(4):299–306.

59 De Nuccio C, Bernardo A, Ferrante A, et al. Adenosine A2A receptor stimulation restores cell functions and differentiation in Niemann-Pick type C-like oligodendrocytes. Sci Rep. 2019;9(1):9782.

60 Hoque M, Rentero C, Conway JR, et al. The cross-talk of LDL-cholesterol with cell motility: insights from the niemann pick type C1 mutation and altered integrin trafficking. Cell Adhes Migr. 2015;9(5):384–391.

61 Garcia-Melero A, Reverter M, Hoque M, et al. Annexin A6 and late endosomal cholesterol modulate integrin recycling and cell migration. J Biol Chem. 2016;291(3):1320–1335.

62 Caswell P, Norman J. Endocytic transport of integrins during cell migration and invasion. Trends Cell Biol. 2008;18(6):257–263.

63 Reynolds R, Wilkin GP. Development of macroglial cells in rat cerebellum. II. An in situ immunohistochemical study of oligodendroglial lineage from precursor to mature myelinating cell. J Biol Chem. 1980;255(2):669–679.

64 March PA, Thrall MA, Brown DE, Mitchell TW, Lowenthal AC, Walkley SU. GABAergic neuroaxonal dystrophy and other cytopathological alterations in feline Niemann-Pick disease type C. Acta Neuropathol. 1997;94(2):164–172.

65 Fog CK. Kirkegaard T. Animal models for Niemann-Pick type C: implications for drug discovery & development. Expert Opin Drug Discov. 2019;14(5):499–509.